Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
$58.40
$51.39
$19.50
$59.76
$22.57B0.26175 shs6 shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$239.46
-0.3%
$254.15
$161.65
$275.00
$12.33B1.4551,438 shs705,117 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$397.56
-2.4%
$397.84
$189.30
$421.00
$12.61B1.38219,086 shs423,395 shs
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
$2.10
-4.5%
$2.31
$1.73
$3.79
$394.95M1.6410.83 million shs33.91 million shs
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$42.98
+0.0%
$42.86
$22.89
$52.23
$4.46B1.581.92 million shs7.39 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00%0.00%+5.43%+31.35%+102.60%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-0.22%+4.16%-9.80%+12.41%+27.64%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-2.36%+3.95%-1.17%+33.66%+90.89%
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
0.00%0.00%0.00%0.00%-26.83%
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.00%0.00%0.00%0.00%+13.28%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.586 of 5 stars
2.34.00.04.73.22.52.5
Medpace Holdings, Inc. stock logo
MEDP
Medpace
4.9851 of 5 stars
3.44.00.04.63.74.23.1
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
0.4853 of 5 stars
2.00.00.00.00.02.51.3
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.4822 of 5 stars
1.00.00.04.50.61.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.64
Moderate Buy$253.235.75% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.80
Moderate Buy$443.0011.43% Upside
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
2.00
Hold$2.4315.87% Upside
Syneos Health, Inc. stock logo
SYNH
Syneos Health
2.00
Hold$43.000.05% Upside

Current Analyst Ratings

Latest SYNH, MEDP, CRL, BTGGF, and SLGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$453.00 ➝ $464.00
4/24/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$446.00 ➝ $454.00
4/23/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$340.00 ➝ $450.00
3/18/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$240.00 ➝ $290.00
3/18/2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$395.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $265.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$215.00 ➝ $250.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$270.00 ➝ $290.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$270.00 ➝ $280.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$252.00 ➝ $268.00
2/15/2024
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.13B2.99$17.30 per share13.84$70.15 per share3.41
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$1.89B6.53$9.84 per share40.41$21.67 per share18.35
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
$97.67M4.04N/AN/A$3.00 per share0.70
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$5.39B0.83$6.72 per share6.40$33.96 per share1.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/A0.00N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$474.62M$9.2126.0019.361.8211.49%16.53%7.02%5/9/2024 (Confirmed)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$282.81M$9.8140.5330.582.0415.92%59.74%19.70%7/22/2024 (Estimated)
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
-$109.16M-$0.69N/AN/AN/A-159.54%-24.72%-21.62%N/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
$266.50M$0.6962.29N/A1.31%8.63%3.66%N/A

Latest SYNH, MEDP, CRL, BTGGF, and SLGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.05N/A-$2.05N/AN/AN/A  
4/22/2024Q1 2024
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.45$3.20+$0.75$3.20$512.39 million$511.00 million    
2/14/2024Q4 2023
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.39$2.46+$0.07$1.30$991.25 million$1.01 billion      
2/12/202412/31/2023
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.22$2.46+$0.24$2.46$498.72 million$498.40 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
N/AN/AN/AN/AN/A
Syneos Health, Inc. stock logo
SYNH
Syneos Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.73
1.52
1.16
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.78
0.64
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
N/A
17.79
17.29
Syneos Health, Inc. stock logo
SYNH
Syneos Health
0.77
1.20
1.20

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
35386.49 millionN/ANot Optionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
21,80051.51 million50.84 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
5,90030.98 million24.69 millionOptionable
Standard BioTools Inc. stock logo
SLGC
Standard BioTools
451188.07 million160.05 millionOptionable
Syneos Health, Inc. stock logo
SYNH
Syneos Health
28,768103.72 million103.37 millionOptionable

SYNH, MEDP, CRL, BTGGF, and SLGC Headlines

SourceHeadline
Marcie Doser to lead influencer marketing for Syneos Health US PRMarcie Doser to lead influencer marketing for Syneos Health US PR
mmm-online.com - April 3 at 4:43 PM
A conversation with the Value & Access team at Syneos HealthA conversation with the Value & Access team at Syneos Health
mmm-online.com - March 18 at 2:31 PM
Syneos Health leaves state jobs deal, months after the Morrisville company goes privateSyneos Health leaves state jobs deal, months after the Morrisville company goes private
newsobserver.com - February 29 at 3:20 PM
Syneos Health cancels hiring goals linked to Morrisville HQSyneos Health cancels hiring goals linked to Morrisville HQ
bizjournals.com - February 28 at 11:58 PM
People to Watch in 2024: Syneos Health CEO Colin ShannonPeople to Watch in 2024: Syneos Health CEO Colin Shannon
bizjournals.com - January 12 at 9:24 AM
Syneos Health Releases 2024 Dealmakers Intentions SurveySyneos Health Releases 2024 Dealmakers' Intentions Survey
finance.yahoo.com - January 9 at 8:24 AM
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
markets.businessinsider.com - January 4 at 2:06 PM
2023 Year in Review: Syneos Health seeks turnaround after $7B deal to go private2023 Year in Review: Syneos Health seeks turnaround after $7B deal to go private
bizjournals.com - December 29 at 9:50 AM
Syneos Health Releases 2024 Health TrendsSyneos Health Releases 2024 Health Trends
finance.yahoo.com - December 20 at 3:07 PM
Syneos Health Appoints Colin Shannon as CEOSyneos Health Appoints Colin Shannon as CEO
pharmexec.com - October 4 at 3:09 PM
Syneos Health Appoints Colin Shannon as Chief Executive OfficerSyneos Health Appoints Colin Shannon as Chief Executive Officer
tmcnet.com - October 3 at 1:12 PM
Days after closing PE buyout, Syneos Health names Colin Shannon as CEODays after closing PE buyout, Syneos Health names Colin Shannon as CEO
mmm-online.com - October 3 at 1:12 PM
Syneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEOSyneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEO
markets.businessinsider.com - October 3 at 1:12 PM
SYNH Syneos Health, Inc.SYNH Syneos Health, Inc.
seekingalpha.com - October 2 at 8:45 PM
Syneos Health goes private after private equity deals; execs land more than $50MSyneos Health goes private after private equity deals; execs land more than $50M
wraltechwire.com - September 29 at 1:21 PM
Syneos Health execs in line for huge payouts with $7B buyoutSyneos Health execs in line for huge payouts with $7B buyout
finance.yahoo.com - September 28 at 7:45 PM
It’s official: Syneos Health goes private in $7.1B PE dealIt’s official: Syneos Health goes private in $7.1B PE deal
mmm-online.com - September 28 at 2:41 PM
Syneos Health Closes Transaction with Private Investment FirmsSyneos Health Closes Transaction with Private Investment Firms
finance.yahoo.com - September 28 at 2:41 PM
Checking in on Syneos Health Inc (SYNH) after recent insiders movementChecking in on Syneos Health Inc (SYNH) after recent insiders movement
knoxdaily.com - September 27 at 6:35 PM
S&P Dow Jones Indices: Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600S&P Dow Jones Indices: Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600
finanznachrichten.de - September 27 at 8:34 AM
Syneos Health Names Terttu Haring President, Clinical Sites & PatientsSyneos Health Names Terttu Haring President, Clinical Sites & Patients
finance.yahoo.com - September 26 at 9:35 AM
Syneos Deadline AlertSyneos Deadline Alert
stockhouse.com - September 25 at 9:28 AM
SYNEOS 72 HOUR DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Syneos To Contact Him Directly To Discuss Their OptionsSYNEOS 72 HOUR DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Syneos To Contact Him Directly To Discuss Their Options
prnewswire.com - September 23 at 11:01 AM
SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact ...SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact ...
businesswire.com - September 23 at 9:27 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bitcoin Group logo

Bitcoin Group

OTCMKTS:BTGGF
Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.
Charles River Laboratories International logo

Charles River Laboratories International

NYSE:CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Medpace logo

Medpace

NASDAQ:MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Standard BioTools logo

Standard BioTools

NASDAQ:SLGC
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
Syneos Health logo

Syneos Health

NASDAQ:SYNH
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.